T. Andrew Crockett
2018
In 2018, T. Andrew Crockett earned a total compensation of $2M as Chief Executive Officer at Carbylan Therapeutics, a 237% increase compared to previous year.
Compensation breakdown
| Bonus | $675,000 |
|---|---|
| Option Awards | $901,976 |
| Salary | $450,000 |
| Other | $15,300 |
| Total | $2,042,276 |
Crockett received $902K in option awards, accounting for 44% of the total pay in 2018.
Crockett also received $675K in bonus, $450K in salary and $15.3K in other compensation.
Rankings
In 2018, T. Andrew Crockett's compensation ranked 5,626th out of 14,244 executives tracked by ExecPay. In other words, Crockett earned more than 60.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,626 out of 14,244 | 61st |
Division Manufacturing | 2,125 out of 5,765 | 63rd |
Major group Chemicals And Allied Products | 784 out of 2,128 | 63rd |
Industry group Drugs | 656 out of 1,817 | 64th |
Industry Pharmaceutical Preparations | 506 out of 1,391 | 64th |
Source: SEC filing on August 23, 2019.
Crockett's colleagues
We found two more compensation records of executives who worked with T. Andrew Crockett at Carbylan Therapeutics in 2018.